Market Overview:
The global viral vector manufacturing market reached a value of US$ XX Billion in 2021. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
A viral vector is a tool used by molecular biologists for delivering genetic materials into cells. It is used to replace defective genes for curing genetic disorders and express and present pathogenic antigens for generating an immune response by mimicking a natural infection. It is widely employed in oncolytic therapies to target and kill tumor cells. Besides this, as it assists in treating different diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it finds extensive applications in life science research, gene therapy and vaccinology. At present, there is a rise in viral vector manufacturing on account of the rising prevalence of genetic disorders due to a combination of gene mutations and damaged chromosomes in the body.
Viral Vector Manufacturing Market Trends:
The increasing cancer patients due to the rising alcohol consumption and sedentary lifestyles of individuals represents one of the key factors contributing to the growth of the market. In addition, there is a rise in the number of clinical studies undertaken on viral vectors across the globe. This, along with the growing utilization of viral vectors in novel drug delivery, is positively influencing the market. Besides this, they are efficient carriers of virus-disabling sequences and are used to deliver HIV-inhibiting transgenes to human hematopoietic stem cells (HSCs). Additionally, governments of several countries are launching campaigns to generate awareness about viral vector vaccines among individuals. They are also improving the regulatory environment via changes, such as fast-track approval processes. Furthermore, key market players are extensively investing in capacity expansion for manufacturing activities around the world. These players are also indulging in mergers and acquisitions (M&A), which is projected to increase their overall sales and profitability.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global viral vector manufacturing market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, disease, application and end user.
Breakup by Type:
- Adenoviral Vectors
- Adeno-associated Viral Vectors
- Lentiviral Vectors
- Retroviral Vectors
- Others
Breakup by Disease:
- Cancer
- Genetic Disorders
- Infectious Diseases
- Others
Breakup by Application:
Breakup by End User:
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V.
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2021 |
| Historical Period |
2016-2021 |
| Forecast Period |
2022-2027 |
| Units |
US$ Billion |
| Segment Coverage |
Type, Disease, Application, End User, Region |
| Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
| Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
| Companies Covered |
Cognate BioServices Inc. (Charles River Laboratories International Inc.), F. Hoffmann-La Roche AG, FinVector Oy, FUJIFILM Holdings Corporation, Kaneka Eurogentec S.A. (Kaneka Corporation), Lonza Group AG, Merck KGaA, Oxford Biomedica plc, REGENXBIO Inc., Sanofi S.A., Thermo Fisher Scientific Inc. and uniQure N.V. |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global viral vector manufacturing market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global viral vector manufacturing market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the disease?
- What is the breakup of the market based on the application?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global viral vector manufacturing market and who are the key players?
- What is the degree of competition in the industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Viral Vector Manufacturing Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Adenoviral Vectors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Adeno-associated Viral Vectors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Lentiviral Vectors
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Retroviral Vectors
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Disease
7.1 Cancer
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Genetic Disorders
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Infectious Diseases
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by Application
8.1 Gene Therapy
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Vaccinology
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by End User
9.1 Pharmaceutical and Biopharmaceutical Companies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Research Institutes
9.2.1 Market Trends
9.2.2 Market Forecast
10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia-Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Cognate BioServices Inc. (Charles River Laboratories International Inc.)
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.2 F. Hoffmann-La Roche AG
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.3 FinVector Oy
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.4 FUJIFILM Holdings Corporation
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.4.4 SWOT Analysis
15.3.5 Kaneka Eurogentec S.A. (Kaneka Corporation)
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.6 Lonza Group AG
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Merck KGaA
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Oxford Biomedica plc
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 REGENXBIO Inc.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.9.4 SWOT Analysis
15.3.10 Sanofi S.A.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Thermo Fisher Scientific Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 uniQure N.V.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
List of Figures
Figure 1: Global: Viral Vector Manufacturing Market: Major Drivers and Challenges
Figure 2: Global: Viral Vector Manufacturing Market: Sales Value (in Billion US$), 2016-2021
Figure 3: Global: Viral Vector Manufacturing Market Forecast: Sales Value (in Billion US$), 2022-2027
Figure 4: Global: Viral Vector Manufacturing Market: Breakup by Type (in %), 2021
Figure 5: Global: Viral Vector Manufacturing Market: Breakup by Disease (in %), 2021
Figure 6: Global: Viral Vector Manufacturing Market: Breakup by Application (in %), 2021
Figure 7: Global: Viral Vector Manufacturing Market: Breakup by End User (in %), 2021
Figure 8: Global: Viral Vector Manufacturing Market: Breakup by Region (in %), 2021
Figure 9: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 10: Global: Viral Vector Manufacturing (Adenoviral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 11: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 12: Global: Viral Vector Manufacturing (Adeno-associated Viral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 13: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 14: Global: Viral Vector Manufacturing (Lentiviral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 15: Global: Viral Vector Manufacturing (Retroviral Vectors) Market: Sales Value (in Million US$), 2016 & 2021
Figure 16: Global: Viral Vector Manufacturing (Retroviral Vectors) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 17: Global: Viral Vector Manufacturing (Other Types) Market: Sales Value (in Million US$), 2016 & 2021
Figure 18: Global: Viral Vector Manufacturing (Other Types) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 19: Global: Viral Vector Manufacturing (Cancer) Market: Sales Value (in Million US$), 2016 & 2021
Figure 20: Global: Viral Vector Manufacturing (Cancer) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 21: Global: Viral Vector Manufacturing (Genetic Disorders) Market: Sales Value (in Million US$), 2016 & 2021
Figure 22: Global: Viral Vector Manufacturing (Genetic Disorders) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 23: Global: Viral Vector Manufacturing (Infectious Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 24: Global: Viral Vector Manufacturing (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 25: Global: Viral Vector Manufacturing (Other Diseases) Market: Sales Value (in Million US$), 2016 & 2021
Figure 26: Global: Viral Vector Manufacturing (Other Diseases) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 27: Global: Viral Vector Manufacturing (Gene Therapy) Market: Sales Value (in Million US$), 2016 & 2021
Figure 28: Global: Viral Vector Manufacturing (Gene Therapy) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 29: Global: Viral Vector Manufacturing (Vaccinology) Market: Sales Value (in Million US$), 2016 & 2021
Figure 30: Global: Viral Vector Manufacturing (Vaccinology) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 31: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market: Sales Value (in Million US$), 2016 & 2021
Figure 32: Global: Viral Vector Manufacturing (Pharmaceutical and Biopharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 33: Global: Viral Vector Manufacturing (Research Institutes) Market: Sales Value (in Million US$), 2016 & 2021
Figure 34: Global: Viral Vector Manufacturing (Research Institutes) Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 35: North America: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 36: North America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 37: United States: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 38: United States: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 39: Canada: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 40: Canada: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 41: Asia-Pacific: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 42: Asia-Pacific: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 43: China: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 44: China: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 45: Japan: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 46: Japan: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 47: India: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 48: India: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 49: South Korea: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 50: South Korea: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 51: Australia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 52: Australia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 53: Indonesia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 54: Indonesia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 55: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 56: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 57: Europe: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 58: Europe: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 59: Germany: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 60: Germany: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 61: France: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 62: France: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 63: United Kingdom: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 64: United Kingdom: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 65: Italy: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 66: Italy: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 67: Spain: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 68: Spain: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 69: Russia: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 70: Russia: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 71: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 72: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 73: Latin America: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 74: Latin America: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 75: Brazil: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 76: Brazil: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 77: Mexico: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 78: Mexico: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 79: Others: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 80: Others: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 81: Middle East and Africa: Viral Vector Manufacturing Market: Sales Value (in Million US$), 2016 & 2021
Figure 82: Middle East and Africa: Viral Vector Manufacturing Market: Breakup by Country (in %), 2021
Figure 83: Middle East and Africa: Viral Vector Manufacturing Market Forecast: Sales Value (in Million US$), 2022-2027
Figure 84: Global: Viral Vector Manufacturing Industry: SWOT Analysis
Figure 85: Global: Viral Vector Manufacturing Industry: Value Chain Analysis
Figure 86: Global: Viral Vector Manufacturing Industry: Porter's Five Forces Analysis
List of Tables
Table 1: Global: Viral Vector Manufacturing Market: Key Industry Highlights, 2021 and 2027
Table 2: Global: Viral Vector Manufacturing Market Forecast: Breakup by Type (in Million US$), 2022-2027
Table 3: Global: Viral Vector Manufacturing Market Forecast: Breakup by Disease (in Million US$), 2022-2027
Table 4: Global: Viral Vector Manufacturing Market Forecast: Breakup by Application (in Million US$), 2022-2027
Table 5: Global: Viral Vector Manufacturing Market Forecast: Breakup by End User (in Million US$), 2022-2027
Table 6: Global: Viral Vector Manufacturing Market Forecast: Breakup by Region (in Million US$), 2022-2027
Table 7: Global: Viral Vector Manufacturing Market: Competitive Structure
Table 8: Global: Viral Vector Manufacturing Market: Key Players